To investigate whether preprogramming (Bereitschaftspotential, BP) and control activity (skilled performance positivity, SPP) in a complex task are sensitive to L-dopa, movement related potentials (MRPs) were recorded in 12 non-demented Parkinson's disease (PD) patients before and after acute L-dopa administration, and in 17 control subjects. After L-dopa administration, the PD patients scored a significantly higher percentage of correct performances ( p<0.05), linked to a decreased BP amplitude ( p<0.001) and an increased SPP amplitude ( p<0.005), than before therapy. Our findings suggest that preprogramming activity is impaired in untreated PD patients. Dopaminergic drug administration seems to restore their ability to use more automatic ...
Parkinson’s disease (PD) is a neurodegenerative disorder that markedly affects voluntary action. Whi...
Movement-related potentials (MRPs) associated with voluntary movements reflect cortical activity ass...
In this study in patients with Parkinson's disease (PD), off and on dopaminergic therapy, with and w...
Objectives: The authors investigated whether preprogramming (Bereitschaftspotential, BP) and control...
This study was designed to evaluate the contribution of central dopaminergic mechanisms to the P300 ...
Investigated were those aspects of motor planning and execution underlying movement dysfunction in p...
BACKGROUND:The goal of this study was to evaluate the effects of L-Dopa medication in Parkinson's di...
Parkinson's disease (PD) is a neurodegenerative disorder characterised by typicalmotor symptoms that...
Objective: To verify whether the change in L-dopa plasma levels after a single dose of carbidopa/L-d...
Objective: To verify whether the change in L-dopa plasma levels after a single dose of controlled re...
Background: Sustained drug therapy in Parkinson’s disease may alter the psychomotor responses to acu...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movemen...
International audienceINTRODUCTION: Behavioral changes in Parkinson's disease are complex and their ...
Parkinson’s disease (PD) is characterized by resting tremor, rigidity and bradykinesia. Dopaminergic...
Parkinson’s disease (PD) is a neurodegenerative disorder that markedly affects voluntary action. Whi...
Movement-related potentials (MRPs) associated with voluntary movements reflect cortical activity ass...
In this study in patients with Parkinson's disease (PD), off and on dopaminergic therapy, with and w...
Objectives: The authors investigated whether preprogramming (Bereitschaftspotential, BP) and control...
This study was designed to evaluate the contribution of central dopaminergic mechanisms to the P300 ...
Investigated were those aspects of motor planning and execution underlying movement dysfunction in p...
BACKGROUND:The goal of this study was to evaluate the effects of L-Dopa medication in Parkinson's di...
Parkinson's disease (PD) is a neurodegenerative disorder characterised by typicalmotor symptoms that...
Objective: To verify whether the change in L-dopa plasma levels after a single dose of carbidopa/L-d...
Objective: To verify whether the change in L-dopa plasma levels after a single dose of controlled re...
Background: Sustained drug therapy in Parkinson’s disease may alter the psychomotor responses to acu...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movemen...
International audienceINTRODUCTION: Behavioral changes in Parkinson's disease are complex and their ...
Parkinson’s disease (PD) is characterized by resting tremor, rigidity and bradykinesia. Dopaminergic...
Parkinson’s disease (PD) is a neurodegenerative disorder that markedly affects voluntary action. Whi...
Movement-related potentials (MRPs) associated with voluntary movements reflect cortical activity ass...
In this study in patients with Parkinson's disease (PD), off and on dopaminergic therapy, with and w...